Idebenone Treatment of Early Parkinson's Diseasesymptoms

Inclusion Criteria: * (1) Male or female, age \> 30 years old, ≤ 80 years old; * (2) Conforms to the "Diagnostic Criteria for Parkinson's Disease" developed by the 2015 International Association of Sports Disabilities (MDS); * (3) Patients with early Parkinson's disease, duration \<3 years, Hoehn-Yahr classification:1-3, MMSE scale score ≥ 24 points; * (4)Receiving a stable dose of dopamine agonist or monoamine oxidase type B inhibitor for treatment before the enrollment; * (5) The subjects need to sign the Informed Consent Form（ICF） Exclusion Criteria: * (1)Patients with disturbance of consciousness, aphasia and mental illness; patients with major depression (HAD scale score ≥ 15 points) * (2)Patients with Parkinson's superimposition syndrome and patients with secondary Parkinson's syndrome (hepatolenticular degeneration, hepatic encephalopathy, cerebellar disease, hydrocephalus, parathyroid disease, etc.) * (3)Patients who have long-term use of dopamine blockers (such as potent neuroleptics, sibutramine, reserpine, metoclopramide, etc.); * (4)Patients who have taken coenzyme Q10 or idebenone within three months; * (5) Patients taking amantadine and levodopa need to stop taking the drug for more than one month before the enrollment; * (6)Patients with severe cardiopulmonary dysfunction, liver and kidney dysfunction (more than 3 times normal); * (7)Patients who cannot cooperate with the neuropsychological test; * (8) Patients with poor compliance, not following the prescribed treatment regimen.